Deubiquitinase OTUD3: a double-edged sword in immunity and disease

Qiao Xu; Lan He; Shubing Zhang; Xiaotang Di; Hao Jiang

doi:10.3389/fcell.2023.1237530

Deubiquitinase OTUD3: a double-edged sword in immunity and disease

Front Cell Dev Biol. 2023 Sep 26:11:1237530. doi: 10.3389/fcell.2023.1237530. eCollection 2023.

Authors

Qiao Xu¹, Lan He², Shubing Zhang¹, Xiaotang Di¹, Hao Jiang³

Affiliations

¹ Department of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, China.
² School of Biomedical Science, Hunan University, Changsha, Hunan, China.
³ Department of Biomedical Informatics, School of Life Sciences, Central South University, Changsha, Hunan, China.

Abstract

Deubiquitination is an important form of post-translational modification that regulates protein homeostasis. Ovarian tumor domain-containing proteins (OTUDs) subfamily member OTUD3 was identified as a deubiquitinating enzyme involved in the regulation of various physiological processes such as immunity and inflammation. Disturbances in these physiological processes trigger diseases in humans and animals, such as cancer, neurodegenerative diseases, diabetes, mastitis, etc. OTUD3 is aberrantly expressed in tumors and is a double-edged sword, exerting tumor-promoting or anti-tumor effects in different types of tumors affecting cancer cell proliferation, metastasis, and metabolism. OTUD3 is regulated at the transcriptional level by a number of MicroRNAs, such as miR-520h, miR-32, and miR101-3p. In addition, OTUD3 is regulated by a number of post-translational modifications, such as acetylation and ubiquitination. Therefore, understanding the regulatory mechanisms of OTUD3 expression can help provide insight into its function in human immunity and disease, offering the possibility of its use as a therapeutic target to diagnose or treat disease.

Keywords: OTUD3; cancer; deubiquitinase; disease; immunity.

Publication types

Review

Grants and funding

This study was supported by the National Natural Science Foundation of China (Grant Nos. 82103184, 81672632, 81972312, and 32000622), the Science and Technology Innovation Program of Hunan Province of China (Grant No. 2022RC1165), the Natural Science Foundation of Hunan Province of China (Grant Nos. 2021JJ40720, 2021JJ30912, 2021JJ40052, and 2022JJ40579), and the Research Project of Health Commission of Hunan Province of China (Grant No. 202202085572).